Shinobi Enhances Leadership Structure for Growth
Shinobi Therapeutics is entering a transformative phase as the biotechnology company announces the appointment of key leadership. To aid in achieving its ambitious goals of scalable, immune-evasive cell therapies, Dr. Luis Borges has been appointed as the first Chief Scientific Officer (CSO) and Dr. Steven Katz as the inaugural Chief Medical Officer (CMO). This strategic move aims to accelerate the company's commitment to developing next-generation therapies, particularly for solid tumors and autoimmune disorders.
Strategic Appointments to Propel Clinical Goals
The recent appointments of Drs. Borges and Katz signal a significant shift in Shinobi's operational strategy. CEO Dan Kemp expressed enthusiasm over the addition of both leaders, highlighting their extensive combined experience in cell therapy and clinical execution. "The addition of Luis and Steven is a game-changer for Shinobi," said Kemp, underlining how their expertise will help in fast-tracking the company’s mission. Their roles will focus on innovative therapy development that is accessible to patients who need it most.
Building a Strong Scientific Advisory Board
Further elevating its research capabilities, Shinobi has expanded its Scientific Advisory Board (SAB) with the inclusion of notable figures in the field of immunotherapy. Renowned experts Dr. Katy Rezvani and Dr. Georg Schett join existing member Dr. Carl June. Each brings a wealth of knowledge and experience that aligns with Shinobi’s technical objectives, making the SAB a formidable asset as the company prepares to advance its clinical trials.
Innovation in Cell Therapy Development
Dr. Steven Katz’s extensive background provides Shinobi with critical insights into clinical oncology and immunotherapeutics. His past experiences include leading numerous clinical trials and securing IND clearance for complex drug-device combinations, equipping him with the necessary foundation to oversee clinical operations. At Shinobi, he aims to conquer challenges presented by solid tumors through streamlined processes and innovative scientific approaches.
Dr. Luis Borges Leads Cutting-Edge R&D
Dr. Borges brings over 28 years of experience in the scientific domain, specializing in induced pluripotent stem cell (iPSC) technologies. Previously, he was the CSO at Century Therapeutics, where he successfully guided the development of their first iPSC-derived product candidate. At Shinobi, he will spearhead the company’s research and development efforts focusing on innovative solutions for cancer and autoimmune therapies.
A Year of Achievements and Partnership Growth
Over the past year, Shinobi has accomplished several significant milestones, including a successful $51 million Series A funding round and the receipt of a large grant of $59 million to support its first clinical trial. This success has set the stage for robust partnership initiatives, collaborating with industry leaders such as Panasonic and Anocca, enhancing the efficiency of their iPSC technology and paving the way for future innovations.
Global Operations and Future Aspirations
Shinobi has also expanded its operational footprint to key international markets, including Japan, allowing the company to leverage the area known as the birthplace of iPSC technology. By establishing a presence there, Shinobi can streamline its clinical trial processes while focusing on delivering breakthrough therapies to patients worldwide.
About Shinobi Therapeutics
Shinobi Therapeutics is committed to addressing the barriers of scalability and accessibility in cell therapies. Their immune-evasive iPS-T cell platform represents a new generation of treatments that can be manufactured off-the-shelf, allowing for broader patient access. This innovative platform promises improved clinical outcomes and addresses economic constraints that typically hinder patient care.
Frequently Asked Questions
What recent appointments were made at Shinobi Therapeutics?
Shinobi appointed Dr. Luis Borges as Chief Scientific Officer and Dr. Steven Katz as Chief Medical Officer to advance their cell therapy initiatives.
What is the focus of Shinobi's new leadership?
The new leadership is focused on developing scalable immune-evasive therapies for solid tumors and autoimmune disorders.
Who are the notable members of Shinobi's Scientific Advisory Board?
The SAB includes Drs. Katy Rezvani, Georg Schett, and Carl June, enhancing Shinobi's expertise in cell therapy.
What significant funding has Shinobi secured recently?
Shinobi secured $59 million in non-dilutive funding from AMED, adding to their successful $51 million Series A round.
What are Shinobi's goals regarding global operations?
Shinobi aims to leverage its presence in Japan for smoother clinical trials while developing innovative therapies on a global scale.
